选择不适合接受顺铂为基础化疗的晚期尿路上皮细胞癌患者的化疗药物。
Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.
机构信息
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
出版信息
Ther Adv Med Oncol. 2010 Nov;2(6):381-8. doi: 10.1177/1758834010376185.
Abstract
Transitional cell carcinoma of the urothelial tract is the second most common cancer of the genitourinary system and the fifth most common cancer in Western countries with more than 300,000 new cases per year worldwide. Following the introduction of cisplatin-based chemotherapy, median overall survival in patients with metastatic disease has doubled, demonstrating chemotherapy as an important treatment modality in advanced or metastatic disease. Patients 'unfit' to receive cisplatin-based chemotherapy are characterized by impaired renal function, impaired performance status, and/or comorbidity that preclude the use of cisplatin. In this review we summarize the different chemotherapeutic schemes, focusing on treatment options in cisplatin 'unfit' patients.
摘要
尿路上皮移行细胞癌是泌尿系统第二大常见癌症，也是西方国家第五大常见癌症，全球每年有超过 30 万例新发病例。随着顺铂为基础的化疗的引入，转移性疾病患者的中位总生存期增加了一倍，表明化疗是晚期或转移性疾病的重要治疗方式。不适合接受顺铂为基础化疗的患者的特点是肾功能受损、体能状态不佳和/或合并症，使顺铂的使用受到限制。在这篇综述中，我们总结了不同的化疗方案，重点介绍了不适合顺铂化疗的患者的治疗选择。
相似文献
1
Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.选择不适合接受顺铂为基础化疗的晚期尿路上皮细胞癌患者的化疗药物。
Ther Adv Med Oncol. 2010 Nov;2(6):381-8. doi: 10.1177/1758834010376185.
2
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.治疗不适合顺铂为基础化疗的转移性尿路上皮癌患者。
J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9.
3
Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.对于不符合顺铂治疗条件的晚期尿路上皮癌患者的化疗选择。
Cancer Treat Rev. 2008 Jun;34(4):328-38. doi: 10.1016/j.ctrv.2007.12.006. Epub 2008 Feb 8.
4
5
Commentary on "Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?" Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108-13 [Epub 2012 Aug 15].评论“非局部浸润性膀胱癌的卡铂为基础的诱导化疗——顺铂不耐受患者的合理替代方案？”Mertens LS，Meijer RP，Kerst JM，Bergman AM，van Tinteren H，van Rhijn BW，Horenblas S，荷兰癌症研究所泌尿科，荷兰阿姆斯特丹安东尼范列文虎克医院：J Urol 2012；188（4）：1108-13 [Epub 2012 年 8 月 15 日]。
Urol Oncol. 2013 Jul;31(5):716-7. doi: 10.1016/j.urolonc.2013.03.012.
6
Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy.预测接受顺铂为基础化疗的转移性上尿路尿路上皮癌患者生存情况的预后模型。
Int J Urol. 2016 May;23(5):385-9. doi: 10.1111/iju.13067. Epub 2016 Mar 14.
7
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.欧洲癌症研究与治疗组织晚期尿路上皮癌研究中原发肿瘤位置对生存的影响。
J Urol. 2018 May;199(5):1149-1157. doi: 10.1016/j.juro.2017.11.068. Epub 2017 Nov 20.
8
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.一线治疗晚期尿路上皮癌的临床证据：当前范例和新兴治疗选择。
Cancer Treat Rev. 2020 Sep;89:102072. doi: 10.1016/j.ctrv.2020.102072. Epub 2020 Jul 22.
9
Evolving Treatment of Advanced Urothelial Cancer.晚期尿路上皮癌的治疗进展
J Oncol Pract. 2017 May;13(5):309-315. doi: 10.1200/JOP.2017.022137.
10
Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?卡铂为基础的诱导化疗用于非肌层浸润性膀胱癌——对不适合顺铂治疗的患者是合理的选择吗？
J Urol. 2012 Oct;188(4):1108-13. doi: 10.1016/j.juro.2012.06.018. Epub 2012 Aug 15.
引用本文的文献
1
The 6-methyladenine erasers ALKBH5 and FTO influence chemotherapy efficiency in bladder cancer cell lines.6-甲基腺嘌呤去甲基化酶ALKBH5和FTO影响膀胱癌细胞系的化疗效率。
Ann Transl Med. 2025 Jun 27;13(3):26. doi: 10.21037/atm-25-7. Epub 2025 Jun 13.
2
Impact of salvage cytotoxic chemotherapy on prognosis in patients with recurrence after radical cystectomy: a multi-institutional retrospective study.根治性膀胱切除术后复发患者挽救性细胞毒性化疗对预后的影响：多机构回顾性研究。
BMC Urol. 2022 May 13;22(1):75. doi: 10.1186/s12894-022-01026-3.
3
Survey of chemotherapy-induced nausea and vomiting in patients with urothelial carcinoma.尿路上皮癌患者化疗引起的恶心和呕吐调查
Mol Clin Oncol. 2021 Oct;15(4):219. doi: 10.3892/mco.2021.2384. Epub 2021 Aug 25.
4
Synergistic Interaction between 5-FU and an Analog of Sulforaphane-2-Oxohexyl Isothiocyanate-In an In Vitro Colon Cancer Model.5-氟尿嘧啶与萝卜硫素-2-氧代己基异硫氰酸盐类似物的协同相互作用-在体外结肠癌模型中。
Molecules. 2021 May 19;26(10):3019. doi: 10.3390/molecules26103019.
5
The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.转移性尿路上皮癌一线靶向治疗的快速演变格局：一项系统综述
Oncologist. 2021 Aug;26(8):e1381-e1394. doi: 10.1002/onco.13827. Epub 2021 Jun 11.
6
Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis.二线治疗策略用于顺铂治疗进展或不适合的尿路上皮癌患者：一项网络荟萃分析。
BMC Urol. 2019 Dec 2;19(1):125. doi: 10.1186/s12894-019-0560-7.
7
The continuing role of chemotherapy in the management of advanced urothelial cancer.化疗在晚期尿路上皮癌治疗中的持续作用。
Ther Adv Urol. 2018 Nov 28;10(12):455-480. doi: 10.1177/1756287218814100. eCollection 2018 Dec.
本文引用的文献
1
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.随机 II/III 期试验评估吉西他滨/卡铂和甲氨蝶呤/卡铂/长春碱在不适合顺铂为基础化疗的晚期尿路上皮癌患者中的应用：EORTC 研究 30986 的 II 期结果。
J Clin Oncol. 2009 Nov 20;27(33):5634-9. doi: 10.1200/JCO.2008.21.4924. Epub 2009 Sep 28.
2
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.对于既往未经治疗的尿路上皮癌患者，每2周给予吉西他滨和紫杉醇治疗。
Cancer. 2009 Jun 15;115(12):2652-9. doi: 10.1002/cncr.24313.
3
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.培美曲塞二钠与吉西他滨用于晚期尿路上皮癌的2期试验（E4802）：东部肿瘤协作组的一项试验
Cancer. 2008 Jun 15;112(12):2671-5. doi: 10.1002/cncr.23503.
4
Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.在铂类方案治疗失败后，每周使用紫杉醇和卡铂治疗晚期移行细胞癌。
Eur Urol. 2007 Oct;52(4):1115-22. doi: 10.1016/j.eururo.2007.03.078. Epub 2007 Apr 5.
5
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.吉西他滨联合顺铂与吉西他滨联合卡铂作为晚期尿路上皮移行细胞癌一线化疗的比较：一项随机2期试验的结果
Eur Urol. 2007 Jul;52(1):134-41. doi: 10.1016/j.eururo.2006.12.029. Epub 2006 Dec 26.
6
Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.多西他赛与吉西他滨联合治疗晚期尿路上皮移行细胞癌：一项II期药理学研究结果
Anticancer Drugs. 2007 Feb;18(2):211-8. doi: 10.1097/CAD.0b013e328010ee5c.
7
A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.培美曲塞联合吉西他滨治疗局部晚期和/或转移性尿路上皮移行细胞癌的II期试验。
Ann Oncol. 2006 Oct;17(10):1533-8. doi: 10.1093/annonc/mdl154. Epub 2006 Jul 27.
8
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.肾功能损害对膀胱尿路上皮癌患者接受基于顺铂的辅助化疗资格的影响。
Cancer. 2006 Aug 1;107(3):506-13. doi: 10.1002/cncr.22031.
9
Systemic chemotherapy in inoperable or metastatic bladder cancer.
Ann Oncol. 2006 Apr;17(4):553-61. doi: 10.1093/annonc/mdj079. Epub 2005 Nov 22.
10
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.每周一次紫杉醇和吉西他滨治疗晚期尿路上皮移行细胞癌：印第安纳肿瘤学组II期研究
J Clin Oncol. 2005 Feb 20;23(6):1185-91. doi: 10.1200/JCO.2005.05.089.
Zotero 插件